Last reviewed · How we verify
CT327 0.5%
CT327 is a selective inhibitor of the 11β-HSD1 enzyme.
CT327 is a selective inhibitor of the 11β-HSD1 enzyme. Used for Treatment of atopic dermatitis.
At a glance
| Generic name | CT327 0.5% |
|---|---|
| Sponsor | Creabilis SA |
| Drug class | 11β-HSD1 inhibitor |
| Target | 11β-HSD1 |
| Modality | Small molecule |
| Therapeutic area | Inflammation |
| Phase | Phase 2 |
Mechanism of action
By inhibiting 11β-HSD1, CT327 reduces the conversion of cortisone to cortisol, thereby decreasing inflammation and potentially treating various inflammatory conditions.
Approved indications
- Treatment of atopic dermatitis
Common side effects
- Injection site reactions
Key clinical trials
- A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis (PHASE2)
- Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris (PHASE2)
- CT 327 in the "Atopy Patch Test" Model (PHASE1)
- CT 327 in the Treatment of Atopic Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |